{
  "nodes": [
    {
      "node_id": "node_A",
      "step_index": 1,
      "timestamp": "2010-01-01T00:00:00Z",
      "commentary": "Initial diagnosis of FH-mutated papillary RCC",
      "data": {
        "demographics": {"age": 46, "sex": "male"},
        "conditions": ["FH-mutated papillary renal cell carcinoma"],
        "treatments": ["partial nephrectomy"],
        "observations": ["Well-defined papillary formations", "Intense vimentin positivity", "Ki67 proliferative index 10%"],
        "metadata": {"doi": "10.1038/s41698-024-00750-3", "journal_id": "npjprecisiononcology2024"}
      }
    },
    {
      "node_id": "node_B",
      "step_index": 2,
      "timestamp": "2011-01-01T00:00:00Z",
      "commentary": "Relapse with radical nephrectomy",
      "data": {
        "conditions": ["Relapsed FH-mutated pRCC"],
        "treatments": ["radical nephrectomy"],
        "metadata": {"doi": "10.1038/s41698-024-00750-3"}
      }
    },
    {
      "node_id": "node_C",
      "step_index": 3,
      "timestamp": "2012-01-01T00:00:00Z",
      "commentary": "Retroperitoneal metastasis with dendritic cell-based vaccination",
      "data": {
        "conditions": ["Metastatic pRCC"],
        "treatments": ["DC-based vaccine"],
        "metadata": {"doi": "10.1038/s41698-024-00750-3"}
      }
    },
    {
      "node_id": "node_D",
      "step_index": 4,
      "timestamp": "2012-06-01T00:00:00Z",
      "commentary": "New abdominal nodules post-DC vaccination, partial response with bevacizumab and erlotinib",
      "data": {
        "conditions": ["Progressive metastatic pRCC"],
        "treatments": ["bevacizumab", "erlotinib"],
        "observations": ["Partial response by RECISTv1.1"],
        "metadata": {"doi": "10.1038/s41698-024-00750-3"}
      }
    },
    {
      "node_id": "node_E",
      "step_index": 5,
      "timestamp": "2017-07-01T00:00:00Z",
      "commentary": "Initial nivolumab therapy with suspected pseudoprogression",
      "data": {
        "conditions": ["Suspected pseudoprogression"],
        "treatments": ["nivolumab"],
        "observations": ["Disease progression on imaging"],
        "metadata": {"doi": "10.1038/s41698-024-00750-3"}
      }
    },
    {
      "node_id": "node_F",
      "step_index": 6,
      "timestamp": "2018-07-01T00:00:00Z",
      "commentary": "Treatment switched to axitinib and metformin with complete metabolic response",
      "data": {
        "conditions": ["Complete metabolic response"],
        "treatments": ["axitinib", "metformin"],
        "observations": ["Complete response on PET imaging"],
        "metadata": {"doi": "10.1038/s41698-024-00750-3"}
      }
    },
    {
      "node_id": "node_G",
      "step_index": 7,
      "timestamp": "2019-01-01T00:00:00Z",
      "commentary": "New mediastinal lesions prompting nivolumab rechallenge",
      "data": {
        "conditions": ["New mediastinal lesions"],
        "treatments": ["nivolumab rechallenge"],
        "observations": ["Lesions resolved completely after nivolumab rechallenge"],
        "labs": ["Significant eosinophilia"],
        "metadata": {"doi": "10.1038/s41698-024-00750-3"}
      }
    },
    {
      "node_id": "node_H",
      "step_index": 8,
      "timestamp": "2020-06-01T00:00:00Z",
      "commentary": "Sustained complete response with ongoing eosinophilia",
      "data": {
        "conditions": ["Sustained complete response"],
        "observations": ["Persistent eosinophilia", "No evidence of active malignancy"],
        "treatments": ["nivolumab discontinuation", "prednisone for eosinophilia"],
        "metadata": {"doi": "10.1038/s41698-024-00750-3"}
      }
    }
  ],
  "edges": [
    {
      "edge_id": "edge_1",
      "from_node": "node_A",
      "to_node": "node_B",
      "step_index": 1,
      "event_type": "SpontaneousChange",
      "changes": [{"field": "conditions", "change_type": "add", "value": "relapse of pRCC"}]
    },
    {
      "edge_id": "edge_2",
      "from_node": "node_B",
      "to_node": "node_C",
      "step_index": 2,
      "event_type": "Observation",
      "changes": [{"field": "conditions", "change_type": "add", "value": "metastatic disease"}]
    },
    {
      "edge_id": "edge_3",
      "from_node": "node_C",
      "to_node": "node_D",
      "step_index": 3,
      "event_type": "Intervention",
      "changes": [{"field": "treatments", "change_type": "composite", "value": ["bevacizumab", "erlotinib"]}]
    },
    {
      "edge_id": "edge_4",
      "from_node": "node_D",
      "to_node": "node_E",
      "step_index": 4,
      "event_type": "Intervention",
      "changes": [{"field": "treatments", "change_type": "add", "value": "nivolumab"}]
    },
    {
      "edge_id": "edge_5",
      "from_node": "node_E",
      "to_node": "node_F",
      "step_index": 5,
      "event_type": "Intervention",
      "changes": [{"field": "treatments", "change_type": "composite", "value": ["axitinib", "metformin"]}]
    },
    {
      "edge_id": "edge_6",
      "from_node": "node_F",
      "to_node": "node_G",
      "step_index": 6,
      "event_type": "Intervention",
      "changes": [{"field": "treatments", "change_type": "update", "from": "axitinib", "to": "nivolumab rechallenge"}]
    },
    {
      "edge_id": "edge_7",
      "from_node": "node_G",
      "to_node": "node_H",
      "step_index": 7,
      "event_type": "Observation",
      "changes": [{"field": "conditions", "change_type": "update", "from": "New mediastinal lesions", "to": "Sustained complete response"}]
    }
  ]
}
